AMP Discovery LLC’s business model is to complete a human Phase I safety trial with our lead drug candidate. We seek to partner with a pharmaceutical company that has an interest in developing novel compounds to replace existing antibiotics. A Phase I SBIR grant was recently awarded to the company. The company will raise $2 million from the investment community and will apply for a Fast Track Phase I/Phase II SBIR grant for approximately $2 million. These funds will enable the company to support AMP manufacturing and IND enabling studies. An additional $10-15 million will be required to carry out phase Ib/IIa clinical trials. Given the promising data we believe our lead compound could receive early FDA approval. Successful completion of the above studies will represent a major milestone.